European Journal of Cancer 51 (2015) 18–26

Paul Ruff A, David R. Ferryb, Radek Lakomý B, Jana Prausová d, Guy A. Van Hazel e , Paulo M. Hoff f, David Cunningham g, Dirk Arnold h, Hans J. Schmoll i, Vladimir M. Moiseyenko j, Joseph J. McKendrick k, Albert J. ten Tije l, Raghu L. Vishwanath m, Pankaj Bhargava n, Soazig Chevalier o, Teresa Macarulla p, Eric Van Cutsem q

a University of Witwatersrand, Faculty of Health Sciences, Johannesburg, South Africa
b Russells Hall Hospital, Dudley, UK
c Masaryk Memorial Cancer Institute, Brno, Czech Republic
d Fakultní nemocnice v Motole, Praha, Czech Republic
e University of Western Australia, Western Australia, Australia
f Centro De Oncologia/Hospital Sirio Libanes, Sa˜o Paulo, Brazil
g The Royal Marsden Hospital, Sutton, UK
h Department of Medical Oncology, Tumor Biology Center, Freiburg, Germany
i Martin Luther University Halle-Wittenberg, Germany
j Oncology Research Institute Na. NN. Petrov, St-Petersburg, Russian Federation
k Monash University, Victoria, Australia
l Amphia Hospital, Breda, The Netherlands
m Sanofi Global Oncology Medical Affairs, Cambridge, MA, United States
n Sanofi Global Oncology Research and Development, Cambridge, MA, United States
o Sanofi, Vitry-sur-Seine, France
p Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Auto`noma de Barcelona, Barcelona, Spain
q University Hospitals Leuven and KU Leuven, Belgium